Elan says US SEC probing Tysabri and bapineuzumab disclosures from 2008
This article was originally published in Scrip
Executive Summary
Elan said in its most recent 6-K filing that the US Securities and Exchange Commission (SEC) is probing press announcements made last year by the firm involving the multiple sclerosis drug Tysabri (natalizumab) and the investigational Alzheimer's disease treatment bapineuzumab.